膜性肾病靶抗原及特异性治疗策略的研究进展  

Research progress on target antigens and specific treatment strategies of membranous nephropathy

作　　者：陆露莹 韩飞 LU Luying;HAN Fei(Department of Nephrology,Shulan(Hangzhou)Hospital,Zhejiang 310004,China;Kidney Disease Center,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China)

机构地区：[1]树兰(杭州)医院肾脏病科,浙江310004 [2]浙江大学医学院附属第一医院肾脏病中心,杭州310003

出　　处：《中国临床新医学》2024年第8期841-845,共5页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：浙江省重点研发计划项目(编号:2020C03034)。

摘　　要：膜性肾病是最常见的原发性肾小球疾病之一。疾病特异性靶抗原如M型磷脂酶A2受体(PLA2R)的发现为膜性肾病的诊治开辟新的思路,尤其为针对B细胞谱系的干预提供了基础,即治疗的核心是减少抗体产生和上皮下免疫复合物沉积。该文从膜性肾病的特异性靶抗原出发,探讨有前景的靶向治疗手段。Membranous nephropathy is one of the most common primary glomerular diseases.The discovery of disease-specific target antigens such as M-type phospholipase A2 receptor(PLA2R)has opened up new ideas for the diagnosis and treatment of membranous nephropathy,especially providing a basis for the intervention of B-cell lineages.The core of treatment is to reduce antibody production and subepithelial immune complex deposition.This paper explores promising targeted therapy methods starting from the specific target antigens of membranous nephropathy.

关 键 词：膜性肾病 靶抗原 B细胞治疗 

分 类 号：R692.6[医药卫生—泌尿科学]